Pathogenic variants in Tropomyosin 2 (TPM2), which encodes a skeletal muscle specific actin binding protein essential for sarcomere function, cause a spectrum of musculoskeletal disorders including Nemaline Myopathy, Cap Myopathy, congenital fiber type disproportion, and distal arthrogrypsosis (DA). TPM2-related disorders have not been modeled in vivo, so we expressed a series of dominant, pathogenic TPM2 variants in Drosophila embryos and found two variants, K49Del and E122K, disrupted muscle morphogenesis and muscle function. Transient overexpression of K49Del and E122K also disrupted muscle morphogenesis in zebrafish. We further developed a benchmarked overexpression assay in zebrafish to characterize TPM2 variants that we identified in DA patients, and found these variants caused musculoskeletal defects similar to those of the known pathogenic variants. In addition, the severity of musculoskeletal phenotypes in zebrafish expressing TPM2 variants correlated with the severity of clinical phenotypes observed in DA patients. Our study establishes transient overexpression in zebrafish as an efficient platform to characterize variants of uncertain significance in vivo, and argues our assays can predict the clinical severity of musculoskeletal associated variants.